Dr. Rawlings’ primary research interests include dysregulated lymphoid development and signaling leading to immunodeficiency, autoimmunity and/or lymphoid malignancies, and the development of gene therapy for immune diseases. His laboratory uses expertise in basic and clinical immunology, signal transduction and developmental biology to understand how altered signals can lead to immunologic disease, with the goal of developing translational therapies that specifically modulate key pathways. Dr. Rawlings is a member of multiple regional and national organizations, participates in various NIH study sections, and ad hoc reviewer for international grant programs and immunology journals. He also directs the Seattle Children’s Program for Cell and Gene Therapy, focused on clinical application of both viral gene therapy and designer nuclease-mediated gene editing in hematopoietic cells for treatment of immune diseases.